Cancer Research Meeting Calendar Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 1308-1314, March 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sorio, C.
Right arrow Articles by Scarpa, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sorio, C.
Right arrow Articles by Scarpa, A.
[Cancer Research 59, 1308-1314, March 15, 1999]
© 1999 American Association for Cancer Research

Molecular Biology and Genetics

The FHIT Gene Is Expressed in Pancreatic Ductular Cells and Is Altered in Pancreatic Cancers1

Claudio Sorio, Antonella Baron, Simonetta Orlandini, Giuseppe Zamboni, Paolo Pederzoli, Kay Huebner and Aldo Scarpa2

Dipartimento di Patologia [C. S., A. B., S. O., G. Z., A. S.] and Dipartimento di Scienze Chirurgiche [P. P.], Università di Verona, I-37134, Verona, Italy; and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [K. H.]

ABSTRACT

We examined 2 normal pancreata, 21 primary pancreatic ductal cancers, and 19 pancreatic cancer cell lines for Fhit expression and FHIT gene status. The normal pancreas expressed Fhit protein in the cytoplasm of ductular cells, whereas interlobular and larger ducts, acini, and insulae of Langerhans were negative. Fhit protein was detected by immunoblot assay in 11 pancreatic cancer cell lines; of the 8 cell lines lacking Fhit protein, 7 lacked FHIT mRNA and 1 showed an abnormally sized transcript. DNA from five of these eight cell lines showed homozygous loss of FHIT exon 5. In 8 of the 21 primary cancers, Fhit expression was detected by immunohistochemistry. Reverse transcription-PCR analysis of 6 of the 13 cases lacking Fhit showed normal-sized FHIT product in 3 cases and a mixture of normal and abnormal products in the other 3. Sequencing showed that abnormal bands were missing variable numbers of exons. Loss of microsatellite DNA markers internal to the FHIT gene was observed in 10 of 13 primary cancers lacking Fhit protein (homozygous in two cases) and in only 1 of the 8 cancers expressing Fhit protein. In nine primary cancers, four expressing and five lacking Fhit protein, it was possible to obtain pure cancer DNA by microdissection. Three of the five microdissected cases lacking Fhit protein exhibited homozygous deletion of FHIT exon 5. In conclusion, the lack of Fhit protein in pancreatic cancers correlated with absence or alteration of FHIT mRNA and was often associated with FHIT gene anomalies.




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
M. Takahashi, T. Kitahashi, R. Ishigamori, M. Mutoh, M. Komiya, H. Sato, Y. Kamanaka, M. Naka, T. Maruyama, T. Sugimura, et al.
Increased expression of inducible nitric oxide synthase (iNOS) in N-nitrosobis(2-oxopropyl)amine-induced hamster pancreatic carcinogenesis and prevention of cancer development by ONO-1714, an iNOS inhibitor
Carcinogenesis, August 1, 2008; 29(8): 1608 - 1613.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y. Takeuchi, M. Takahashi, K. Sakano, M. Mutoh, N. Niho, M. Yamamoto, H. Sato, T. Sugimura, and K. Wakabayashi
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor {gamma}
Carcinogenesis, August 1, 2007; 28(8): 1692 - 1696.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
C. Schleicher, C. Poremba, H. Wolters, K.-L. Schafer, N. Senninger, and M. Colombo-Benkmann
Gain of Chromosome 8q: A Potential Prognostic Marker in Resectable Adenocarcinoma of the Pancreas?
Ann. Surg. Oncol., April 1, 2007; 14(4): 1327 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
F. Trapasso, S. Yendamuri, K. R. Dumon, R. Iuliano, R. Cesari, B. Feig, R. Seto, L. Infante, H. Ishii, A. Vecchione, et al.
Restoration of receptor-type protein tyrosine phosphatase {eta} function inhibits human pancreatic carcinoma cell growth in vitro and in vivo
Carcinogenesis, November 1, 2004; 25(11): 2107 - 2114.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. I. Wistuba, R. Ashfaq, A. Maitra, H. Alvarez, E. Riquelme, and A. F. Gazdar
Fragile Histidine Triad Gene Abnormalities in the Pathogenesis of Gallbladder Carcinoma
Am. J. Pathol., June 1, 2002; 160(6): 2073 - 2079.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
D. Bodmer, M. Eleveld, E. Kater-Baats, I. Janssen, B. Janssen, M. Weterman, E. Schoenmakers, M. Nickerson, M. Linehan, B. Zbar, et al.
Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21)
Hum. Mol. Genet., March 1, 2002; 11(6): 641 - 649.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Uematsu, A. Yoshimura, A. Gemma, H. Mochimaru, Y. Hosoya, S. Kunugi, K. Matsuda, M. Seike, F. Kurimoto, K. Takenaka, et al.
Aberrations in the Fragile Histidine Triad (FHIT) Gene in Idiopathic Pulmonary Fibrosis
Cancer Res., December 1, 2001; 61(23): 8527 - 8533.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Tsujiuchi, Y. Sasaki, N. Murata, M. Tsutsumi, Y. Konishi, and D. Nakae
FHIT alterations in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats
Carcinogenesis, December 1, 2001; 22(12): 2017 - 2022.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce
Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies
JAMA, November 21, 2001; 286(19): 2441 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
K. M. Anderson and J. E. Harris
Selected Features of Nonendocrine Pancreatic Cancer
Experimental Biology and Medicine, June 1, 2001; 226(6): 521 - 537.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. R. Dumon, H. Ishii, A. Vecchione, F. Trapasso, G. Baldassarre, F. Chakrani, T. Druck, E. F. Rosato, N. N. Williams, R. Baffa, et al.
Fragile Histidine Triad Expression Delays Tumor Development and Induces Apoptosis in Human Pancreatic Cancer
Cancer Res., June 1, 2001; 61(12): 4827 - 4836.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
P. S. Moore, G. Zamboni, A. Brighenti, D. Lissandrini, D. Antonello, P. Capelli, G. Rigaud, M. Falconi, and A. Scarpa
Molecular Characterization of Pancreatic Serous Microcystic Adenomas : Evidence for a Tumor Suppressor Gene on Chromosome 10q
Am. J. Pathol., January 1, 2001; 158(1): 317 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Ouyang, L.-j. Mou, C. Luk, N. Liu, J. Karaskova, J. Squire, and M.-S. Tsao
Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype
Am. J. Pathol., November 1, 2000; 157(5): 1623 - 1631.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Mori, K. Mimori, T. Shiraishi, H. Alder, H. Inoue, Y. Tanaka, K. Sugimachi, K. Huebner, and C. M. Croce
Altered Expression of Fhit in Carcinoma and Precarcinomatous Lesions of the Esophagus
Cancer Res., March 1, 2000; 60(5): 1177 - 1182.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
R. Baffa, L. G. Gomella, A. Vecchione, P. Bassi, K. Mimori, J. Sedor, C. M. Calviello, M. Gardiman, C. Minimo, S. E. Strup, et al.
Loss of FHIT Expression in Transitional Cell Carcinoma of the Urinary Bladder
Am. J. Pathol., February 1, 2000; 156(2): 419 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. P. Hao, J. E. Willis, T. G. Pretlow, J. S. Rao, G. T. MacLennan, I. C. Talbot, and T. P. Pretlow
Loss of Fragile Histidine Triad Expression in Colorectal Carcinomas and Premalignant Lesions
Cancer Res., January 1, 2000; 60(1): 18 - 21.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Mimori, T. Druck, H. Inoue, H. Alder, L. Berk, M. Mori, K. Huebner, and C. M. Croce
Cancer-specific chromosome alterations in the constitutive fragile region FRA3B
PNAS, June 22, 1999; 96(13): 7456 - 7461.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Y. Y. Fong, V. Fidanza, N. Zanesi, L. F. Lock, L. D. Siracusa, R. Mancini, Z. Siprashvili, M. Ottey, S. E. Martin, T. Druck, et al.
Muir-Torre-like syndrome in Fhit-deficient mice
PNAS, April 25, 2000; 97(9): 4742 - 4747.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.